• Careers
  • Investors
  • News
  • Partnering
  • Contact Us
 
  • Home
  • Our Products
    • Recent Products
    • Consumer Products
    • Medical Devices & Diagnostics
    • Prescription Products
    • Product Coupons
  • Our Caring
    • Our Stories
    • Our Giving
    • Our Responsibility
    • Protecting Our People
    • Company Initiatives
  • Our Company
    • Our Credo Values
    • Our Management Approach
    • Our Citizenship
    • Corporate Governance
    • Company Structure
    • Our People & Diversity
    • Company Publications
    • Our History
  • News
    • All News
    • Corporate News
    • Product And Operating Company News
    • Financial News
    • Media Contacts
    • Product And Operating Company News Archive
  • Text Size
  • Text Only
  • Email to a Friend
  • Printer Friendly
  • RSS

Product and Operating Company News

Need to know more about a new skin care product? A new surgical device? A new pain relief medication? You can search here for the information you need from a Johnson & Johnson company.

< Prev | | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | .... 34 Next >
Janssen Biotech, Inc. Announces Collaborative Development And Worldwide License Agreement For Investigational Anti-Cancer Drug, PCI-32765

December 08, 2011

First Patient Enrolled In Therakos Phase Two Study For Treatment Of Graft-Versus-Host Disease

December 07, 2011

Casey Abrams Announces Winners Of Inflammatory Bowel Disease Awareness Campaign After A National Vote

December 02, 2011

EDURANT® (Rilpivirine) Approved In Europe For Treatment-Naïve Adults With HIV-1 Infection With A Baseline Viral Load ≤ 100,000 HIV-1 RNA Copies/mL

November 28, 2011

Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

November 13, 2011

Janssen Pharmaceutical Companies Launch Healthy Minds Initiative to Spur Neuroscience Collaboration and Support Millions Suffering from Brain Disorders

November 11, 2011

< Prev | | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | .... 34 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Employees
  • Careers
  • Investors
  • News
  • Partnering
  • Contact Us
Johnson & Johnson
  • Home
  • Our Products
  • Our Caring
  • Our Company
  • All News
  • Corporate News
  • Product And Operating Company News
  • Financial News
  • Media Contacts
  • Product And Operating Company News Archive
  • Text Size
  • Graphic Version
  • Email to a Friend
  • Printer Friendly
  • RSS

Product and Operating Company News

Need to know more about a new skin care product? A new surgical device? A new pain relief medication? You can search here for the information you need from a Johnson & Johnson company.

This section contains multiple pages. Click on each page number to advance the page.
< Prev | | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | .... 34 Next >
Janssen Biotech, Inc. Announces Collaborative Development And Worldwide License Agreement For Investigational Anti-Cancer Drug, PCI-32765

December 08, 2011

First Patient Enrolled In Therakos Phase Two Study For Treatment Of Graft-Versus-Host Disease

December 07, 2011

Casey Abrams Announces Winners Of Inflammatory Bowel Disease Awareness Campaign After A National Vote

December 02, 2011

EDURANT® (Rilpivirine) Approved In Europe For Treatment-Naïve Adults With HIV-1 Infection With A Baseline Viral Load ≤ 100,000 HIV-1 RNA Copies/mL

November 28, 2011

Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

November 13, 2011

Janssen Pharmaceutical Companies Launch Healthy Minds Initiative to Spur Neuroscience Collaboration and Support Millions Suffering from Brain Disorders

November 11, 2011

< Prev | | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | .... 34 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •